Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 30

Sort by

Sort Order Select

Journal Articles

Can Circulating Tumor DNA Improve the Predictive Value of Interim Response in Patients with Advanced Hodgkin Lymphoma and PET-2 DS3?

Heidi Mocikova, Kristyna Kupcova, Jana Markova, Lubica Gaherova, Maria Maco, Iva Hamova, Adriana Velasova, Alice Sykorova, Pavla Stepankova, Alexandra Kredatusova, Vit Prochazka, Jan Koren, Petr Nehasil, Petra Zemankova, Tomas Kozak, Ondrej Havranek

Blood (2024) 144 (Supplement 1): 6193.

https://doi.org/10.1182/blood-2024-210890

Published: 2024

Journal Articles

Is It Better to Start Treatment with ABVD and Continue with PET2-Adapted Approach or Should We Use 2 Cycles of Beacopp Escalated and 2 Cycles of ABVD and Irradiation in Early Unfavorable Hodgkin Lymphoma?

Heidi Mocikova, Jana Markova, Lubica Gaherova, Maria Maco, Alice Sykorova, David Belada, Marie Lukasova, Vit K Prochazka, Katarina Hradska, Juraj Ďuraš, Ondrej Havranek, Tomas Kozak

Blood (2021) 138 (Supplement 1): 4539.

https://doi.org/10.1182/blood-2021-148363

Published: 2021

Journal Articles

Dose-Intensification in Early Unfavorable Hodgkin Lymphoma: Long-Term Follow up of the German Hodgkin Study Group (GHSG) HD14 Trial

Sarah Gillessen, MD, Annette Plütschow, Michael Fuchs, MD, Jana Markova, MD, Richard Greil, MD, Max S. Topp, MD, Julia Meissner, MD, Josée M Zijlstra, MD PhD, Dennis A. Eichenauer, Volker Diehl, MD, Peter Borchmann, MD PhD, Andreas Engert, MD, Bastian von Tresckow, MD

Blood (2019) 134 (Supplement_1): 129.

https://doi.org/10.1182/blood-2019-125249

Published: 2019

Journal Articles

Early Interim PET in Patients with Advanced-Stage Hodgkin's Lymphoma Treated within the Phase 3 GHSG HD18 Study

Blood (2017) 130 (Supplement 1): 737.

https://doi.org/10.1182/blood.V130.Suppl_1.737.737

Published: 2017

Journal Articles

Elderly Hodgkin Lymphoma - Multicenter Retrospective Data Analysis from the Czech Hodgkin Lymphoma Registry

Alice Sýkorová, MD PhD, Heidi Mocikova, MD PhD, Vit Prochazka, MD PhD Assoc Prof, Marie Lukasova, MD, Pavla Stepankova, MD, David Belada, MD PhD, Katerina Klaskova, MA, Lubica Gaherova, MD, Karel Chroust, MA, PhD, Jana Markova, MD

Blood (2017) 130 (Supplement 1): 2792.

https://doi.org/10.1182/blood.V130.Suppl_1.2792.2792

Published: 2017

Journal Articles

Immune Response in Acute Myeloid Leukemia with Mutated Nucleophosmin

Katerina Kuzelova, PhD, Barbora Brodská, PhD, Jana Marková, Grzegorz Helbig, MD PhD, Slawomira Kyrcz-Krzemien, MD PhD, Petr Cetkovsky, MD MBA, PhD

Blood (2015) 126 (23): 2572.

https://doi.org/10.1182/blood.V126.23.2572.2572

Published: 2015

Journal Articles

Outcome of Patients with Hodgkin Lymphoma transformed from Chronic Lymphocytic Leukemia

Heidi Mocikova, MD, PhD, Jana Markova, MD, Lubica Gaherova, MD, Lukas Smolej, MD, PhD, Assoc.Prof., Martin Simkovic, MD, Tomas Kozak, MD, PhD, Prof.

Blood (2015) 126 (23): 5298.

https://doi.org/10.1182/blood.V126.23.5298.5298

Published: 2015

Journal Articles

Primary Progressive Disease in Hodgkin Lymphoma Patients: A Retrospective Analysis from the German Hodgkin Study Group

Stefanie Kreissl, MD, Helen Goergen, Bastian von Tresckow, MD, Karolin Behringer, MD, Jana Markova, MD, Andreas Lohri, MD, Julia Meissner, MD, Josée M Zijlstra, MD, Richard Greil, MD, Max S. Topp, MD, Martin Sökler, MD, Hartmut Döhner, MD, Volker Diehl, MD, Andreas Engert, MD, Peter Borchmann, MD

Blood (2015) 126 (23): 3941.

https://doi.org/10.1182/blood.V126.23.3941.3941

Published: 2015

Journal Articles

Addition of Rituximab to BEACOPP escalated to Improve the Outcome of Early Interim PET Positive Advanced Stage Hodgkin Lymphoma Patients: Second Planned Interim Analysis of the HD18 Study.

Peter Borchmann, MD, Heinz Haverkamp, Andreas Lohri, MD, Stefanie Kreissl, MD, Richard Greil, MD, Jana Markova, MD, Michaela Feuring-Buske, MD, Julia Meissner, MD, Ulrich Dührsen, Nicole Engel, MD, Ulrich Keller, MD, Georg Maschmeyer, MD, Markus Dietlein, MD, Carsten Kobe, MD, Michael Fuchs, MD, Volker Diehl, MD, Andreas Engert, MD

Blood (2014) 124 (21): 500.

https://doi.org/10.1182/blood.V124.21.500.500

Published: 2014

Journal Articles

The ASXL1 Gene Alterations in Patients with Myeloid Diseases and Chromosomal 20q Deletion

Jana Brezinova, PhD, Iveta Sarova, PhD, Halka Lhotska, Sarka Ransdorfova, PhD, Silvia Izakova, Karla Svobodova, Jana Markova, Zuzana Zemanova, Ass. Prof.,PhD, Jaroslav Cermak, MD PhD As. Prof., Anna T. Jonasova, MD, Kyra Michalova, PhD Prof.

Blood (2014) 124 (21): 5596.

https://doi.org/10.1182/blood.V124.21.5596.5596

Published: 2014

Journal Articles

CBFβ/MYH11 Hypomethylation Signature In Patients With Acute Myeloid Leukaemia

Hana Hajkova, Markus H.-Y. Fritz, Jiri Schwarz, Jana Markova, Martin Vostry, Zdenek Krejcik, Cyril Salek, Ota Fuchs, PhD, Petr Cetkovsky, Jaroslav Cermak, Cedrik Haskovec, Vladimir Benes

Blood (2013) 122 (21): 3774.

https://doi.org/10.1182/blood.V122.21.3774.3774

Published: 2013

Journal Articles

Relative Reduction of Residual Tumor Improves Outcome Prediction of PET After Effective Chemotherapy for Patients with Advanced Stage Hodgkin Lymphoma

Andreas Engert, MD, Carsten Kobe, MD, Heinz Haverkamp, Georg Kuhnert, Jana Markova, MD, Andreas Lohri, MD, Susanne Klutmann, MD, Holger Amthauer, MD, Volker Diehl, MD, Peter Borchmann, MD, Markus Dietlein, MD

Blood (2012) 120 (21): 3684.

https://doi.org/10.1182/blood.V120.21.3684.3684

Published: 2012

Journal Articles

Outcome of Nodular Lymphocyte Predominant Hodgkin Lymphoma Patients Treated with or without Rituximab

Heidi Mocikova, MD, PhD, Jozef Michalka, MD, Jan Koren, Pavla Stepankova, Alexander Wild, Ludek Raida, MD, Jana Markova, MD, Zdenek Kral, Marek Trneny, MD, Karel Indrak, MD, Prof., Jiri Mayer, M.D., PhD., Prof., Tomas Kozak, M.D., Ph.D.

Blood (2012) 120 (21): 4878.

https://doi.org/10.1182/blood.V120.21.4878.4878

Published: 2012

Journal Articles

Treatment of Stage I-II A Non-Bulky Hodgkin's Lymphoma (HL): An Individual Patient-Data Comparison of German Hodgkin Study Group (GHSG) HD10 and HD11 Combined-Modality Therapy (CMT) and NCIC Clinical Trials Group (NCIC CTG) HD.6 ABVD Alone

Blood (2012) 120 (21): 548.

https://doi.org/10.1182/blood.V120.21.548.548

Published: 2012

Journal Articles

Phase 2 study of PVAG (prednisone, vinblastine, doxorubicin, gemcitabine) in elderly patients with early unfavorable or advanced stage Hodgkin lymphoma

Boris Böll, Henning Bredenfeld, Helen Görgen, Teresa Halbsguth, Hans T. Eich, Martin Soekler, Jana Markova, Ulrich Keller, Ullrich Graeven, Stephan Kremers, Michael Geissler, Guido Trenn, Michael Fuchs, Bastian von Tresckow, Dennis A. Eichenauer, Peter Borchmann, Andreas Engert

Blood (2011) 118 (24): 6292–6298.

https://doi.org/10.1182/blood-2011-07-368167

Published: 2011

Journal Articles

DNMT3A Mutations Are Connected with Lower DNA Methylation Levels and Numbers of Concurrently Hypermethylated Genes in AML Patients

Hana Hajkova, Jana Markova, Cedrik Haskovec, PhD, Jaroslav Cermak, Radka Petrbokova, Kyra Michalova, PhD, Jiri Schwarz, MD, PhD

Blood (2011) 118 (21): 4629.

https://doi.org/10.1182/blood.V118.21.4629.4629

Published: 2011

Journal Articles

Expression Pattern of WT1 Isoforms in Patients with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) and Severe Aplastic Anemia (SAA)

Karolina Kramarzova, Andre Willasch, Bernd Gruhn, Jiri Schwarz, MD, PhD, Jana Markova, Jan Stary, M.D., Jan Trka, MD, PhD, Ludmila Boublikova

Blood (2011) 118 (21): 2502.

https://doi.org/10.1182/blood.V118.21.2502.2502

Published: 2011

Journal Articles

MicroRNA Analysis in the Cerebrospinal Fluid and Blood Serum of Lymphoma Patients At Diagnosis and in Response to Therapy,

Vit Pospisil, Heidi Mocikova, MD, PhD, Milada Jankovska, MD, Jana Markova, MD, Lubica Gaherova, MD, Tomas Kozak, MD, PhD, Tomas Stopka, MD, PhD

Blood (2011) 118 (21): 3663.

https://doi.org/10.1182/blood.V118.21.3663.3663

Published: 2011

Journal Articles

Reduced Intensity of Chemotherapy and PET-Guided Radiotherapy in Patients with Advanced Stage Hodgkin Lymphoma: The GHSG HD15 Final Results

Andreas Engert, MD, Heinz Haverkamp, Carsten Kobe, MD, Jana Markova, MD, Christoph Renner, MD, Anthony D. Ho, MD, PhD, Josée Zijlstra, MD, Zdenek Král, MD, Harald Stein, MD, Hans Theodor Eich, MD, Rolf-Peter Müller, MD, Markus Dietlein, MD, Peter Borchmann, MD, Volker Diehl, MD

Blood (2011) 118 (21): 589.

https://doi.org/10.1182/blood.V118.21.589.589

Published: 2011

Journal Articles

Assessment of Residual Bulky Tumor Using FDG-PET In Patients with Advanced-Stage Hodgkin Lymphoma After Completion of Chemotherapy: Final Report of the GHSG HD15 Trial

Andreas Engert, MD, Carsten Kobe, Jana Markova, Heinz Haverkamp, Peter Borchmann, Felicitas Hitz, Josee Zijlstra, Hans Eich, Rolf-Peter Mueller, Markus Dietlein, Volker Diehl

Blood (2010) 116 (21): 764.

https://doi.org/10.1182/blood.V116.21.764.764

Published: 2010

NARROW

Can Circulating Tumor DNA Improve the Predictive Value of Interim Response in Patients with Advanced Hodgkin Lymphoma and PET-2 DS3?

Is It Better to Start Treatment with ABVD and Continue with PET2-Adapted Approach or Should We Use 2 Cycles of Beacopp Escalated and 2 Cycles of ABVD and Irradiation in Early Unfavorable Hodgkin Lymphoma?

Dose-Intensification in Early Unfavorable Hodgkin Lymphoma: Long-Term Follow up of the German Hodgkin Study Group (GHSG) HD14 Trial

Early Interim PET in Patients with Advanced-Stage Hodgkin's Lymphoma Treated within the Phase 3 GHSG HD18 Study

Elderly Hodgkin Lymphoma - Multicenter Retrospective Data Analysis from the Czech Hodgkin Lymphoma Registry

Immune Response in Acute Myeloid Leukemia with Mutated Nucleophosmin

Outcome of Patients with Hodgkin Lymphoma transformed from Chronic Lymphocytic Leukemia

Primary Progressive Disease in Hodgkin Lymphoma Patients: A Retrospective Analysis from the German Hodgkin Study Group

Addition of Rituximab to BEACOPP escalated to Improve the Outcome of Early Interim PET Positive Advanced Stage Hodgkin Lymphoma Patients: Second Planned Interim Analysis of the HD18 Study.

The ASXL1 Gene Alterations in Patients with Myeloid Diseases and Chromosomal 20q Deletion

CBFβ/MYH11 Hypomethylation Signature In Patients With Acute Myeloid Leukaemia

Relative Reduction of Residual Tumor Improves Outcome Prediction of PET After Effective Chemotherapy for Patients with Advanced Stage Hodgkin Lymphoma

Outcome of Nodular Lymphocyte Predominant Hodgkin Lymphoma Patients Treated with or without Rituximab

Treatment of Stage I-II A Non-Bulky Hodgkin's Lymphoma (HL): An Individual Patient-Data Comparison of German Hodgkin Study Group (GHSG) HD10 and HD11 Combined-Modality Therapy (CMT) and NCIC Clinical Trials Group (NCIC CTG) HD.6 ABVD Alone

Phase 2 study of PVAG (prednisone, vinblastine, doxorubicin, gemcitabine) in elderly patients with early unfavorable or advanced stage Hodgkin lymphoma

DNMT3A Mutations Are Connected with Lower DNA Methylation Levels and Numbers of Concurrently Hypermethylated Genes in AML Patients

Expression Pattern of WT1 Isoforms in Patients with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) and Severe Aplastic Anemia (SAA)

MicroRNA Analysis in the Cerebrospinal Fluid and Blood Serum of Lymphoma Patients At Diagnosis and in Response to Therapy,

Reduced Intensity of Chemotherapy and PET-Guided Radiotherapy in Patients with Advanced Stage Hodgkin Lymphoma: The GHSG HD15 Final Results

Assessment of Residual Bulky Tumor Using FDG-PET In Patients with Advanced-Stage Hodgkin Lymphoma After Completion of Chemotherapy: Final Report of the GHSG HD15 Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only